Smart antibodies for cancer patients
Developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein Olfactomedin-like protein 3 (Olfml3).
Abologix is a biopharmaceutical company based in Geneva, Switzerland. The company is a spin out from the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva and the Geneva University Hospitals.
The company is developing two monoclonal antibodies that selectively block two novel pharmacological targets. Several oncological medical indications are being pursued.
Junction Adhesion Molecule C (JAM-C)
Junction Adhesion Molecule C (JAM-C) has been studied at the laboratories of Prof. Beat Imhof and Prof. Thomas Matthes at the Université de Genève for over 10+ years (36 peer reviewed publications). There is in addition 60+ publications from other laboratories. JAM-C is expressed by certain lymphocytes and prominently localises to tight junctions of endotelial cells. In many lymphoma cells, JAM-C is expressed.
Olfactomedin-like protein 3 (Olfml3)
Olfactomedin-like protein 3 (Olfml3) creates an angiogenic environment in tumours and is associated with vascular growth factors BMP-4 and PDGF. Olfml3 is overexpressed in some cancers. Blocking Olfml3 with highly specific monoclonal antibodies is therefore a logical scientific approach in order to develop new generation inhibitors of angiogenesis. Abologix has produced several recombinant anti-Olfml3 monoclonal antibodies.
Ignacio Faus PhD
Ph.D. in Biochemistry from Indiana University
MBA from the Kellogg Graduate School of
Management, Northwestern University
20+ years of experience in the pharmaceutical and biotechnology industries (BMS-Inserm, Uriach, Ferrer, Palau Pharma, The Sage Group, DRI Capital)
Beat Imhof PhD
Professor at the Medical Faculty, University of Geneva
Studied biochemistry at ETH in Zurich
PhD at the Max Planck Institute in Tubingen where he studied cell-cell contacts
20+ years researching the role of cell adhesion molecules in cancer
Thomas Matthes MD
Professor at the Hematology Service of the University of Geneva
Studied medicine at the Universities of Ulm, Lausanne and Geneva
Specialized in internal medicine and hematology at Pasteur Institute in Paris, and at the Universities of Giessen and Geneva